# DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients

> **NCT02834468** · PHASE3 · UNKNOWN · sponsor: **Shandong University** · enrollment: 100 (estimated)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** DEX Combined With RTX, CSA and IVIG

## Key facts

- **NCT ID:** NCT02834468
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2018-07
- **Final completion:** 2018-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2016-07-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02834468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02834468, "DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02834468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*